Vice President of Clinical Development, Insilico Medicine
Appears in 1 story
Joined Insilico in late 2024 to lead non-oncology programs
Insilico Medicine dosed the first patient this week in a Phase III trial of Rentosertib, a drug for the progressive lung disease idiopathic pulmonary fibrosis. It's the first medicine with both an AI-identified target and an AI-designed molecule to reach this stage of testing.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
